Among the study participants, 230/508 (45.3%) had Alzheimer’s disease biomarkers available (e.g. amyloid PET scan or determination of amyloid-beta and p-tau in cerebrospinal fluid). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.